Tiziana life sciences ltd. receives nasdaq deficiency notice

New york, june 17, 2022 (globe newswire) -- tiziana life sciences (nasdaq:  tlsa ) ("tiziana" or the "company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today disclosed the receipt of a notice (the “notice”) on june 14, 2022 from the nasdaq stock market llc (“nasdaq”) that the company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the company's common shares on the nasdaq global market, as set forth in nasdaq listing rule 5450(a)(1) (the “minimum bid price requirement”). the notice indicated that, consistent with nasdaq listing rule 5810(c)(3)(a), the company has 180 days, or until december 12, 2022 (the “compliance deadline”), to regain compliance with the minimum bid price requirement by having the closing bid price of the company's common shares meet or exceed $1.00 for at least ten consecutive business days.
TLSA Ratings Summary
TLSA Quant Ranking